Former FDA Deputy Director Charged With Insider Trading for Leaking Non-Public Approval Information
By Zachary Brennan -
Published 15 June 2016
A former Deputy Director of the US Food and Drug Administration’s (FDA) Office of Generic Drugs (OGD) was charged on Wednesday for providing tips on drug approvals to three hedge fund managers that made tens of millions off of the non-public information.
Categories: News, US, CDER, Clinical, Crisis management, Drugs
Tags: FDA, OGD, insider trading, FDA non-public information, securities trading with non-public information